Literature DB >> 18582795

Targeting the COPD exacerbation.

Marc Decramer1, Linda Nici, Stefano Nardini, Jane Reardon, Carolyn L Rochester, Claudio M Sanguinetti, Thierry Troosters.   

Abstract

Exacerbations of COPD have a profound detrimental effect on the patient and impose a significant burden on healthcare resource utilization. Prevention and treatment of exacerbations are major objectives of the clinical management of COPD. For this approach to be successful, clinicians must combine both pharmacologic approaches and non-pharmacologic strategies aimed at improving the patient's disease management. Non-pharmacologic approaches include those that can be incorporated into the office setting as well as intervention strategies that are integrated into the lifelong management of COPD. These strategies include developing a partnership with the patient and their social supports, encouraging and facilitating smoking cessation, immunizations, proper use of supplemental oxygen, and most importantly, giving the patient the tools to manage their illness appropriately. Moreover there is clear evidence of an irrevocable decline in pulmonary function after each exacerbation, usually resulting in reduced physical activity and impaired skeletal muscle function. Not surprisingly, pulmonary rehabilitation after such events has been shown to prevent relapse, improve survival and enhance patients' overall function after acute exacerbations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582795     DOI: 10.1016/S0954-6111(08)70003-9

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

1.  Missing potential opportunities to reduce repeat COPD exacerbations.

Authors:  Anne C Melzer; Laura M Feemster; Jane E Uman; David H Ramenofsky; David H Au
Journal:  J Gen Intern Med       Date:  2012-12-08       Impact factor: 5.128

2.  Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation.

Authors:  Takashi Angata; Takeo Ishii; Takashi Motegi; Ritsuko Oka; Rachel E Taylor; Paula Campos Soto; Yung-Chi Chang; Ismael Secundino; Cong-Xiao Gao; Kazuaki Ohtsubo; Shinobu Kitazume; Victor Nizet; Ajit Varki; Akihiko Gemma; Kozui Kida; Naoyuki Taniguchi
Journal:  Cell Mol Life Sci       Date:  2013-03-22       Impact factor: 9.261

3.  The complexity of managing COPD exacerbations: a grounded theory study of European general practice.

Authors:  Mette Bech Risør; Mark Spigt; R Iversen; M Godycki-Cwirko; N Francis; A Altiner; E Andreeva; K Kung; H Melbye
Journal:  BMJ Open       Date:  2013-12-05       Impact factor: 2.692

4.  Exacerbations in patients with chronic obstructive pulmonary disease receiving physical therapy: a cohort-nested randomised controlled trial.

Authors:  Emmylou Beekman; Ilse Mesters; Erik J M Hendriks; Jean W M Muris; Geertjan Wesseling; Silvia M A A Evers; Guus M Asijee; Annemieke Fastenau; Hannah N Hoffenkamp; Rik Gosselink; Onno C P van Schayck; Rob A de Bie
Journal:  BMC Pulm Med       Date:  2014-04-26       Impact factor: 3.317

Review 5.  Diesel exhaust: current knowledge of adverse effects and underlying cellular mechanisms.

Authors:  Sandro Steiner; Christoph Bisig; Alke Petri-Fink; Barbara Rothen-Rutishauser
Journal:  Arch Toxicol       Date:  2016-05-10       Impact factor: 5.153

6.  The effects of smoking and smoking cessation on nasal mucociliary clearance, mucus properties and inflammation.

Authors:  Daniela Mitiyo Odagiri Utiyama; Carolina Tieko Yoshida; Danielle Miyuki Goto; Tômas de Santana Carvalho; Ubiratan de Paula Santos; Andreas Rembert Koczulla; Paulo Hilário Nascimento Saldiva; Naomi Kondo Nakagawa
Journal:  Clinics (Sao Paulo)       Date:  2016-07       Impact factor: 2.365

Review 7.  Impact and prevention of severe exacerbations of COPD: a review of the evidence.

Authors:  David Mg Halpin; Marc Miravitlles; Norbert Metzdorf; Bartolomé Celli
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-10-05

8.  Smoking load reduction is insufficient to downregulate miR-301b, a lung cancer promoter.

Authors:  Camila Dos Santos Arcas; Hui Tzu Lin-Wang; Iracema Ioco Kikuchi Umeda; Márcio Gonçalves de Sousa; Daniela Mitiyo Odagiri Utiyama; Antonio de Padua Mansur; Mariangela Macchione; Mario Hiroyuki Hirata; Naomi Kondo Nakagawa
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.